Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Postherpetic Neuralgia.
Status: Recruiting

The goal of this clinical trial is to evaluate safety and efficacy of percutaneous peripheral nerve stimulation in patients with postherpetic neuralgia. The main questions it aims to answer are:

The efficacy of percutaneous peripheral nerve stimulation in patients with postherpetic neuralgia
The safety of percutaneous peripheral nerve stimulation in patients with postherpetic neuralgia Participants are going to undergo procedure that implant peripheral nerve stimulation electrode produced by Jiangsu CED Medtech Co., Ltd. Then the subjects, whose VAS scores decrease more 30% than baseline level, are classified into two groups randomly. One of the group receiving active stimulation called trial group and another receiving placebo stimulation called control group. All subjects are required to make their own subjects' pain diary to record VSA score before and after implantation until at the end of follow-up. Also, participants are asked to report use of analgesic medications, number of awakenings and adverse events.

Researchers will compare pain scores between the two groups to see if peripheral nerve stimulation is effective to patients with postherpetic neuralgia.

Eligibility:
- EligibilityCriteria: Inclusion criteria:  18 years old and above, male or female Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy; Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery; The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment; Visual analogue scale for pain within 24 hours before surgery ≥ 5; The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form;  Exclusion criteria:  Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously; Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.); Subjects with severe psychological and/or mental disorders and/or non therapeutic drug dependence; Subjects expected to undergo MRI examination within 30 days after PNS implantation; Expected to be discharged within 48 hours or less; Target nerve damage or muscle defects in known pain areas; Subjects who are known to be allergic to skin contact materials (tape or adhesive); Allergy to anesthetics such as lidocaine; Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction; Pregnant women, lactating women, or women planning to have children within the next three months; Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment; Other situations that the researcher deems unsuitable for participation in this clinical trial - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult